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Abstract
Background: The Eph receptors are the largest receptor tyrosine kinase family. Several family
members are expressed in hematopoietic cells. Previously, the expression of a member of this
family, EphA2, was identified on dendritic like cells in tonsils. We therefore specifically examined
the expression of EphA2 on in vitro generated dendritic cells.
Results: In this study, expression of the EphA2 receptor was identified on in vitro generated
Langerhans like dendritic cells compared to in vitro generated dendritic cells. We show that ligand
induced engagement of the EphA2 receptor leads to receptor autophosphorylation indicating a
functional receptor signaling pathway in these cells. We also observe phosphorylation and
dephosphorylation of distinct proteins following ligand activation of EphA receptors. In co-
stimulation assays, receptor-ligand interaction reduces the capacity of the Langerhans like dendritic
cells to stimulate resting CD4+ T cells.
Conclusion: Engagement of EphA receptor tyrosine kinases on Langerhans like dendritic cells
induces signaling as shown by tyrosine phosphorylation and dephosphorylation of distinct proteins.
Furthermore this engagement renders the cells less capable of stimulating CD4+ T cells.
Background
Immature dendritic cells are localized in tissues where
they monitor the microenvironment and are character-
ized by their capacity to take up antigens. Dendritic cells
must be activated by "danger signals" to become efficient
antigen presenting cells [1-3]. This maturation process
includes an efficient presentation of processed antigens by
inducing cell surface expression of peptide loaded MHC
molecules and an increased production of cytokines. Up-
regulation of specific co-stimulatory and co-adhesive mol-
ecules, like CD80 and CD86, are also necessary to fully
activate T cells. Finally, a potential to migrate to the lymph
nodes is developed. The mature dendritic cell is thus
equipped with a package of information that orchestrates
the T cell response [4]. Dendritic cells can be divided into
several groups, with different cellular origins, localization
and capacity to stimulate a primary T cell response [1].
One group is the Langerhans cells, which are immature
dendritic cells of myeloid origin resident in squamous
epithelia, including skin and mucosa. These cells are char-
acterized by high cell surface expression of CD1a and E-
cadherin, in addition to the presence of Birbeck granules
with langerin [5]. Recently, it has been shown that Lang-
erhans like cells can be generated in vitro from both adher-
ent monocytes and CD34+ bone marrow cells in the
presence of transforming growth factor β (TGF-β) [6,7].
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Previously, we have investigated the expression of Eph
receptor tyrosine kinases and their ligands in lymphoid
tissues [8,9]. The Eph kinases are the largest known sub-
family of receptor tyrosine kinases with 15 distinct mem-
bers highly conserved from insects to man [10]. The Eph
receptor tyrosine kinases bind a family of ligands called
ephrins, consisting of two subclasses, ephrin-A and
ephrin-B [10]. The six ephrin-A ligands are anchored to
the membrane by a glycosylphosphatidylinositol (GPI)-
tail, while the three ephrin-B ligands are transmembrane
molecules. Members of both the Eph tyrosine kinases and
the ephrin ligands mediate signaling after receptor-ligand
interaction [11-17]. This bi-directional signaling are
known to affect processes involving cellular interaction,
like cell adhesion, cell migration and tissue border forma-
tion [16-18]. In particular, signaling through both the Eph
kinases and the ephrin ligands have been shown to affect
cellular adhesion through integrins [14,19-22]. One
receptor of the Eph family, EphA2, is expressed in rat
intestine and skin [23], and in fetal mouse skin and the
epithelial lining of the esophagus [24]. Previously, we
have shown the presence of EphA2 mRNA in several
human hematopoietic tissues, and also identified protein
expression in an adherent tonsil cell population with a
dendritic appearance [8]. The aim of this study was there-
fore to identify a dendritic cell population expressing
EphA2 and further investigate its functional role.
Here, we present the selective expression of EphA2 on in
vitro generated Langerhans like dendritic cells. Functional
signaling through EphA receptors is revealed by induced
tyrosine phosphorylation and dephosphorylation of dis-
tinct proteins. Ligation of EphA receptors with a ligand
reduces the capacity of Langerhans like dendritic cells to
stimulate resting CD4+ T cells.
Results and Discussion
In vitro generated Langerhans like dendritic cells (LLDC) 
express the EphA2 receptor tyrosine kinase
Previously, we reported the expression of the EphA2
receptor tyrosine kinase on dendritic like cells in tonsil
[8], and we therefore set out to investigate the potential
role for this receptor in antigen presenting cells. E-cad-
herin, an adhesion molecule expressed by Langerhans
cells, is known to regulate both the expression and the
function of the EphA2 receptor tyrosine kinase [6,25,26].
It has been shown that E-cadherin expression is required
for EphA2 receptor localization at cell-cell contacts in epi-
thelial cells. In the absence of functional E-cadherin,
EphA2 does not reach the cell surface but instead localizes
to the perinuclear region [25]. Therefore in vitro generated
LLDC was tested for the expression of E-cadherin and the
EphA2 receptor. Adherent mononuclear cells, isolated
from blood, were grown for one week in the presence of
GM-CSF, IL-4 and with or without TGF-β to generate
LLDC and dendritic cells, respectively [6]. In line with pre-
The EphA2 receptor tyrosine kinase is expressed by in vitro generated LLDC Figure 1
The EphA2 receptor tyrosine kinase is expressed by in vitro generated LLDC Adherent mononuclear cells were 
isolated and cultured one week in the presence of GM-CSF and IL-4 (for monocyte derived dendritic cells, DC) and TGF-β (for 
monocyte derived LLDC). (A) Cells were incubated with a monoclonal EphA2 antibody (bold line) or an irrelevant antibody 
(dotted line) followed by staining with PE-labeled α-mouse antibody. (B) Cells were incubated with a soluble EphA2 ligand 
fusion protein (ephrin-A4-Fc, bold line) and a negative control fusion protein (CD19-Fc, dotted line). (C) A Western blot with 
cell lysates from monocyte derived dendritic cells (DC) or LLDC (LLDC) were immunoblotted using a polyclonal anti-EphA2 
antiserum.BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/9
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viously published data, the LLDC expressed cell surface E-
cadherin while the dendritic cells did not (data not
shown). Flow cytometry analysis of cells stained with a
monoclonal anti-EphA2 antibody (figure 1A) or an solu-
ble EphA2-ligand, ephrin-A4-Fc [8] respectively, revealed
significant cell surface expression of the EphA2 receptor
on LLDC, and much lower expression on dendritic cells
generated without TGF-β (figure 1B). In addition, total
EphA2 protein expression level was assessed in the two
cell populations by Western blot analysis. Comparable to
the cell surface expression of EphA2, a much higher level
of total EphA2 protein was observed in the LLDC com-
pared to the dendritic cells (figure 1C).
By PCR, the expression of other EphA members in LLDC
was also tested (EphA1, A2, A3, A4, A5, A7, A8). In addi-
tion to EphA2, expression of EphA1 could also be
detected (data not shown). In this study, we have not
investigated the expression of EphA1 at the protein level.
Thus, we cannot exclude that EphA1 is involved in the
functional effects observed after ligand binding presented
below.
During the preparation of this manuscript, the expression
of EphA2 was reported on epidermis residing Langerhans
cells [27].
Ephrin-A induces signaling through EphA receptor kinases 
in LLDC
Several different ephrin ligands of the ephrin-A family can
bind and activate the EphA2 receptor tyrosine kinase [28].
We have previously shown that both the genes encoding
EphA2 and an EphA2 ligand, ephrin-A4, are expressed in
several hematopoietic tissues like lymph node, spleen and
Expression of ephrin-A4 on CD4+ T cells Figure 2
Expression of ephrin-A4 on CD4+ T cells Isolated CD4+ T cells were stimulated with anti-CD3/CD28 Dynabeads for the 
indicated times before staining with an anti-ephrin-A4 antibody (panel A) or EphA2-Fc (panel B). 10000 cells were analyzed. 
Highest expression of cell surface bound ephrin-A4 was observed after three days of stimulation.BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/9
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fetal liver [8]. In addition, we have observed ephrin-A1
mRNA expression in tonsils (data not shown). Thus, both
ephrin-A1 and ephrin-A4 might be in vivo candidate lig-
ands for EphA receptors expressed on Langerhans cells.
We have previously shown that T cells express ephrin-A4
mRNA after anti-CD3 stimulation [8]. Further, we also
show here that expression of ephrin-A4 protein is induced
on CD4+ T cells stimulated with anti-CD3/CD28 Dyna-
beads, and reaches maximal expression after three days of
stimulation (figure 2). Thus, ephrin-A4 expressed on acti-
vated T cells might be a physiological ligand for EphA
receptors expressed on LLDC.
The first event that takes place after interaction between
an Eph receptor and its ligand is autophosphorylation of
the intracellular part of the Eph receptor. To validate the
functionality of the receptor-ligand interaction, the phos-
phorylation level of EphA2 after ephrin-A4 cross-linking
was investigated. LLDC were incubated with immobilized
ligand (ephrin-A1-Fc) or a control fusion protein (CD19-
Fc) for ten minutes at 37°C. The cells were then lysed and
the EphA2 receptor was immunoprecipitated with a poly-
clonal anti-EphA2 antiserum. The phosphorylation status
of the receptor was analyzed using a anti-phosphotyrosine
specific antibody. In agreement with previous studies
[28], tyrosine phosphorylation of EphA2 was observed
after cross-linking with ephrin-A1 (figure 3A). The filter
was stripped and re-probed with anti-EphA2 antiserum to
confirm equal loading of proteins (figure 3A).
Phosphorylation of EphA2 was also seen after incubation
with ephrin-A4-Fc (data not shown). The results show
that the EphA2 receptor expressed on LLDC is functional
and respond by auto-phosphorylation after ligand
activation.
To further investigate the signaling capacity of EphA
receptors, cells were incubated with bead coupled ephrin-
A1-Fc for 10, 20 and 30 min, and then fractionated into
The ephrin-A4 ligand induces signaling through EphA receptors Figure 3
The ephrin-A4 ligand induces signaling through EphA receptors A. Serum starved LLDC were left untreated 
(untreated) incubated with immobilized ephrin-A4-Fc or a control protein (CD19-Fc) for 10 minutes. The EphA2 receptor was 
immunoprecipitated, and the phosphorylation status of the EphA2 kinase was analyzed by Western blot analysis with an anti-
phosphotyrosine antibody (upper panel). The blot was stripped and reprobed with a polyclonal anti-EphA2 antibody (lower 
panel). B. Serum starved LLDC were incubated with immobilized ephrin-A1-Fc for 10, 20, and 30 min, and cell lysates were 
fractioned in cytosol and membrane fraction. Shown in the figure are gel-separated proteins from the membrane fraction 
hybridized with anti-phosphotyrosine antibody (PY99; upper panel). Arrows indicate phosphorylation or dephosphorylation of 
distinct proteins during the time course. The filter was stripped and hybridized with an anti-HLA antibody to verify protein 
loading (lower panel).BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/9
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cytosol and membrane fractions followed by SDS-PAGE
separation, blotting and hybridization with an anti-phos-
photyrosine antibody. Distinct differences in the protein
tyrosine phosphorylation pattern were observed after
ephrin-A1-Fc receptor ligation in the membrane fraction
(figure 3B). In particular, a protein with approximately
molecular mass of 70 kDa was phosphorylated upon 20
and 30 min incubation with ephrin-A1, while dephos-
phorylation of a protein with approximately molecular
mass of 35 kDa was observed already after 10 min incuba-
tion (figure 3B). Several proteins have been reported to be
phosphorylated after ephrin ligation of EphA receptors
like Fak, paxillin and p130Cas [29], or dephosphorylated
like Fak and paxillin [30,31]., depending on the cell sys-
tem applied. None of these proteins correlate with the
estimated molecular mass of the phosphorylated and
dephosphorylated proteins identified in LLDC (figure
3B). The transient phosphorylation and dephosphoryla-
tion patterns observed after stimulation of Eph receptors
involve distinct phosphatases. Shp-2 can associate with
EphA2 and might be involved in dephosphorylation of
FAK and paxillin leading to dissociation of the EphA2-
FAK complex [30]. Low-molecular-weight phosphotyro-
sine phosphatase (LMW-PTP) can be recruited to EphB2
receptor complexes after ephrin ligation [31]. Whether
these phosphatases are involved in EphA signaling in
LLDC awaits further studies.
Engagement of Eph receptors does not influence the cell 
surface expression of accessory- and adhesion molecules 
of LLDC
Interaction between an antigen presenting cell (APC) and
a responding T cell induce signaling inside the APC, in
addition to activation of the T cells. Although there is
detailed information about the functional signaling
response in the T cell after contact with an APC presenting
specific antigen, less is known about the consequences for
the APC. TRANCE and CD40L present on the CD4+ T cell
are known to induce a survival signal for the APC and
license the APC to activate CD8+ T cells, respectively [33-
36]. The interaction of antigen specific CD8+ T cells may
also induce a response in the dendritic cell, as measured
by IL-12 production by the dendritic cells [37]. One may
therefore speculate whether signaling through EphA
kinases may interfere with the T cell induced maturation
of the dendritic cell. To investigate whether EphA receptor
signaling affects the maturation status of the LLDC, the
cells were cultured for 18 hours in the presence of immo-
bilized ephrin-A4-Fc or negative control fusion protein
(CD19-Fc). Cell surface expression of accessory and differ-
entiation/activation molecules (CD18, CD11a, CD11c,
CD49d, CD80, CD86, CD83, HLA-DR, CD40, CD58 and
E-Cadherin) was analyzed by flow cytometry. None of
these molecules showed differences in the expression
pattern between cells grown on immobilized ephrin-A4-
Fc or CD19-Fc (figure 4 and data not shown).
Effect of engagement of EphA receptors on LLDC on the 
proliferative response of T cells in co-culture assays
Based on the observation that EphA activation led to
changes in the tyrosine phosphorylation pattern; we
investigated if EphA receptor ligation had any conse-
quence for the capacity of the LLDC to activate T cells. An
allogeneic assay was performed with increasing numbers
Cell surface expression of activation markers on monocyte  derived LLDC after EphA receptor engagement Figure 4
Cell surface expression of activation markers on 
monocyte derived LLDC after EphA receptor 
engagement LLDC were cultured 18 hours in the presence 
of immobilized ephrin-A4-Fc (bold lines) or the negative con-
trol protein CD19-Fc (dotted lines). Cell surface expressions 
of the indicated molecules were detected by flow cytometry 
analysis. 10000 cells were analyzed.BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/9
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of LLDC or dendritic cells in co-culture with 50 000 CD4+
T cells in the presence of either immobilized ephrin-A4-Fc
or CD19-Fc (control protein). T cell proliferation was
measured as thymidine uptake on day 6–7. For this exper-
iment ephrin-A4 was chosen since we observed binding of
ephrin-A1-Fc to T cells, as shown by others, but only weak
or no binding of ephrin-A4-Fc (data not shown).
In a co-culture with LLDC and CD4+ T cells, the presence
of immobilized ephrin-A4 resulted in reduced T cell pro-
liferation (figure 5A). Soluble ephrin-A4-Fc had no effect
on T cell proliferation (data not shown). The effect was
most pronounced at a high T cell: LLDC ratio. Important,
for dendritic cells (generated without TGF-β), grown with
or without immobilized ephrin-A4, no differences in
CD4+ T cell proliferation were observed (figure 5B)
excluding a direct effect through T cells.
Also a syngeneic antigen presentation assay, using the
recall antigen PPD from mycobacterium, was performed.
Increased numbers of LLDC, on either immobilized
ephrin-A4-Fc or CD19-Fc, were co-cultured with 50000
CD4+ T cells in the presence of PPD. Also here, ligation of
EphA receptors with immobilized ephrin-A4 resulted in
reduced T cell proliferation indicating that the reduction
in the stimulatory capacity of the LLDC is independent of
the presented antigen. As shown for the allogeneic assay
(figure 5A), the effect was most pronounced at a high T
cell: LLDC ratio (figure 5C). Thus, the reduction in T cell
proliferation is most pronounced when sub-optimally
stimulating the T cell.
Dendritic cells strictly regulate the quantity of a T cell
response. Adhesion molecules are involved in the synapse
formation and adhesion between antigen presenting cells
and T cells influence the activation. In addition, rearrange-
ments of the actin cytoskeletal in dendritic cells are neces-
sary for optimal stimulation of resting T cells [38]. Bi-
directional signaling through the Eph receptors and
ephrin ligands influence both the shape and the adhesive
properties of cells, by affecting integrin affinity and the
cytoskeleton [16,18]. In addition, MAPK activation has
been shown to result in inhibition of adhesion to extracel-
lular matrix [32]. MAPK activation has also been shown to
influence activation and maturation of dendritic cells
[39,40]. Thus, one may speculate that a reduced contact
between the LLDC and the T cell, possibly through
integrin deactivation, inhibits stimulation of T cells,
although we did not observe any difference in expression
of β2 integrins (CD18, CD11a and CD11c). In contrary, a
recent report presents results that indicates increased
adhesion of EphA2 expressing dendritic cells derived from
CD34+ progenitors to fibronectin coated surfaces in the
presence of ephrin-A3 through β1 integrin activation [27].
Signaling through EphA receptors reduces the stimulatory  capacity of LLDC to activate CD4+T cells Figure 5
Signaling through EphA receptors reduces the stimu-
latory capacity of LLDC to activate CD4+T cells The 
indicated numbers of antigen presenting cells were used to 
stimulate 50000 CD4+ cells in the presence of immobilized 
control fusion protein (CD19-FC, open columns) or ephrin-
A4-Fc (filled column). T cell proliferation was measured by 
3H-thymidine incorporation on day 6–7. One of at least 
three representative experiments is shown here, the values 
are the mean of triplicates with the SD indicated. (A) An allo-
geneic presenting assay with LLDC (LLDC). (B) An allogeneic 
presenting assay with monocyte derived dendritic cells (DC). 
(C) An autologous antigen-presenting assay with LLDC 
(LLDC) pulsed with tuberculosis PPD antigen.BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/9
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Alternatively, the activation of Eph kinases induces trans-
location to caveolae-like domains, thus; engagement of
EphA receptors on LLDC with immobilized ligand may
induce ectopic raft aggregates, and thereby destabilize the
immunological synapse [41,42]. We have not tested if
secretions of soluble factors important for T cell activation
are affected after EphA receptor activation on LLDC. Thus
we cannot exclude that altered secretion might lead to the
observed reduced T cell proliferation.
Cross-linking of EphA receptors on LLDC does not change 
the cytokine profile indicative of a Th1 or Th2 response
On the background of the results presented in figure 5, we
found it interesting to examine the functional quality of
the T cells resulting from co-culture. A reduced number of
the re-stimulated T cells expressed the activation marker
CD25 when the T cells where co-cultivated in the presence
of immobilized ephrin-A4-Fc compared to the CD19-Fc
(table 1). The effect is most pronounced when suboptimal
stimulating the T cells with a high T cell: LLDC ratio (table
1). This is in accordance with the inhibition of prolifera-
tion measured by thymidine incorporation (figure
5A,5C).
Functional activation of CD4+ T cells induces the expres-
sion of cytokines indicative for Th1 or Th2 responses. Dif-
ferent factors such as the number and type of antigen
presenting cells, co-stimulatory molecules and the dura-
tion of T cell receptor stimulation influence the polariza-
tion of the T cell response, although cytokines are the
dominant regulators [43,44]. To investigate if EphA liga-
tion had a selective effect on polarization of effector cell,
autologous CD4+ T cells were cultured one week with
LLDC in the presence of either immobilized ephrin-A4-Fc
or CD19-Fc, before re-stimulation with TPA and ionomy-
cin. The T cells were then analyzed for the expression of
cytokines indicative of either a Th1 (IFN-γ) or a Th2
response (IL-4) by flow cytometry. Although EphA recep-
tor ligation reduced the number of T cells expressing the
indicated cytokines on a general basis compared to CD19-
Fc, no selective reduction in either of the Th1 or Th2 pop-
ulations were seen (table 1). This demonstrates that EphA
receptor signaling in LLDC does not influence these func-
tional properties of CD4+ T cells.
Since the reduction in proliferation of CD4+ T cells is
more pronounced at a high CD4+: LLDC ratio, the differ-
entiation status of these cells in a mixed lymphocyte
reaction was also studied with higher numbers of LLDC.
In accordance with what is reported in the literature, we
observed in our system an increased number of T cells
producing cytokines, especially the Th1 cytokine IFN-γ,
when decreasing the CD4+: LLDC ratio (table 1). In con-
clusion, engagement of EphA receptors on LLDC does not
seem to affect the polarization of CD4+ T cells, which may
indicate that the effect is through inhibition of adhesion.
Conclusions
The presence of several Eph receptor tyrosine kinases and
ephrin ligands in cells involved in immune responses
suggest a functional role for these genes in immunity
[8,41,45,46]. However, the molecular mechanism still
remains elusive. Here we specifically present expression of
the EphA2 receptor tyrosine kinase on monocyte derived
LLDC. The activation of EphA receptor tyrosine kinases on
these cells reduces the potential of monocyte derived
LLDC to activate CD4+ T cells. The outcome of signaling
through Eph receptors has been demonstrated to be either
increased adhesion or decreased adhesion dependent on
the cell system studied. Although the mechanism for the
reduced T cell proliferation remains unknown, one might
speculate that it is due to a reduced interaction between
the LLDC and T cells, or that EphA ligation inhibits acti-
vation and maturation of the LLDC. CD4+ T cells acquire
an Eph ligand, ephrin-A4, after stimulation with CD3/
CD28, and thus these cells might interact with Langerhans
cells  in vivo e.g. in lymph nodes through this ligand.
Interestingly, several Eph receptors and ephrin ligands are
ectopically expressed in cancers, e.g. both EphA2 and
ephrin-A1 are over-expressed in aggressive melanomas
[47,48]. It is tempting to speculate that the influence of
Eph and ephrin interactions in immunity play a role in
the etiology of cancer, in addition to the increased angio-
geneic potential and the effect on migration of metastatic
cells [49].
Methods
Antibodies, cytokines and fusion proteins
Monoclonal anti-EphA2 was a kind gift from Dr. R.A
Lindberg [23] and polyclonal α-EphA2 was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phos-
photyrosine antibodies: PY99 (Santa Cruz) and 4G10
(Upstate Biotechnology, Lake Placid, NY). Secondary anti-
Table 1: Expression of differentiation and activation markers on 
re-stimulated CD4+ cells
IFN-g, % pos IL4, % pos CD25, % pos
CD19-Fc, 1:100 3.0 2.3 10.3
ephrin-A4-Fc, 1:100 1.9 1.4 6.1
CD19-Fc, 1:10 10.2 2.6 19.3
ephrin-A4-Fc, 1:10 7.4 2.1 17.3
The reduction in T cell proliferation is not a result of a change in the 
Th1/Th2 ratio, but rather a general reduction in the activation status 
of the T cells. Resting CD4+ cells were stimulated one week with 
LLDC, in the presence of immobilized control protein or ligand, and 
re-stimulated 5 hours with TPA and ionomycin. One of three 
representative experiments is shown, and data represent percent of 
living cells staining the indicated antibody.BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/9
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body for Western blot hybridization: α-mouse-HRP
(DAKO, Copenhagen, Denmark). Antibodies used for
flow cytometry analysis: α-CD25 (DAKO), α-CD80 (Bec-
ton Dickinson, SanJose, CA), α-CD83 (Immunotech,
Marseilles, France), α-CD86 (PharMingen, San Diego,
CA),  α-HLA-DR (Becton Dickinson), α-E-Cadherin
(Zymed Laboratories Inc, San Francisco, CA), phycoery-
trin-labeled (PE) – or Fluorescein (FITC)-labeled (F) α-
mouse Ig polyclonal antibody (Ig-RPE and Ig-RF, South-
ern Biotechnology Associates, Birmingham, AL, USA), α-
IL-4-PE and α-INFγ-FITC (PharMingen). IL-4 was a kind
gift from Schering-Plough Research Institute (Kenilworth,
J), TGF-β1 was obtained from Habersham Pharmacia Bio-
tech (Uppsala, Sweden) and GM-CSF was obtained from
Roche (Mannheim, Germany). Fusion proteins of the
extracellular part of either CD19 (negative control pro-
tein) or ephrin-A4 fused to the mouse constant and hinge
region of IgG2b heavy chain is previously described in [8].
Ephrin-A1-Fc fusion protein was generated as described in
[8], with gene specific primers.
Cell isolation and treatments
Mononuclear cells were obtained from Buffy coat from
normal, healthy donors using the lymph prep kit
(Nycomed Pharma, Oslo, Norway). Platelet numbers
were reduced by 8 min. centrifugation at 180 g. 20 × 106
mononuclear cells were seeded per well in a 6-well plate
(Costar Corp., Cambridge, MA), and non-adherent cells
were removed by extensive washing after incubation at
37°C for two hours. Cells were grown for one week in
RPMI 1640, supplemented with 10% FCS, 200 ng/ml GM-
CSF and 100 ng/ml IL-4. For the generation of LLDC, 10
ng/ml rhTGF-β1 were added in addition. Fresh medium
supplemented with cytokines was added at day 2–3. Any
remaining B and T cells were depleted with anti-CD19 and
anti-CD3 coated Dynabeads (Dynal Biotech, Oslo, Nor-
way) before experiments with LLDC. CD4+ T cells were
isolated using anti-CD4 coated Dynabeads (Dynal) and
resting CD4+ T cells were obtained using negative
depletion with anti-MHC class II Dynabeads (Dynal).
CD3/CD28 stimulation of CD4+ T cells was performed
with 2 Dynabeads (Dynal) per T cell. All cells were grown
in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS) at 37°C in a humidified atmosphere
with 5 % CO2.
Antigen presentation assays
Round-bottom 96-well tissue culture plates were coated
with 10 ug/ml α-mouse-IgG in 50 mM Tris-HCl pH 9.5,
blocked with 0.1% BSA, and finally incubated with 20 ug/
ml of the indicated fusion proteins in PBS. Indicated num-
bers of dendritic cells were seeded along with 50000
CD4+ cells in RPMI-1640 medium supplemented with
5% FCS and antibiotics. In addition, for autologue pres-
entation assay, 2 ng/ml PPD ("purified protein deriva-
tive") from Mycobacterium tuberculosis (Veterinary
Institute, Oslo, Norway) were added. At day 6–7, the cells
were pulsed with 3.7 × 104 Bq/well 3H-thymidine ON. The
cells were harvested in a 96-well harvester (Packard, Meri-
den, CT), and incorporated thymidine was measured with
a Top Count liquid scintillation counter (Packard). All
experiments were performed in triplicate.
Subcellular fractionation
LLDC were stimulated with ephrin-A1-Fc for the indicated
times, then washed in ice-cold phosphate-buffered saline
(PBS) and resuspended in buffer A (5 mM Tris-HCl, pH
8,0.5 mM EDTA, 75 mM sucrose and proteinase inhibi-
tors) and sonicated four times 15 s. Nuclei were pelleted
by centrifugation at 400 g for 5 min 4°C in a microsentri-
fuge. The supernatants were centrifuged at 32 000 g for 30
min at 4°C in a Beckmann centrifuge. The supernatants
was collected and used as the cytosol fraction. The mem-
brane pellets were washed three times with PBS, solubi-
lised in buffer A containing 1 % Triton X-100 for 15 min
at 4°C and then centrifuged at 10 000 g for 10 min at 4°C
in a microsentrifuge. Supernatants were used as the mem-
brane fraction.
Phosphorylation, immunoprecipitation and Western blot
LLDC were serum starved (1% FBS) over night and
washed in PBS. Prewarmed cells were then incubated with
Ephrin-A1-Fc coated on anti-mouse Ig magnetic beads
(five beads/cell; Dynal, Oslo, Norway) for the indicated
times at 37°C before resuspension in buffer A, sonication
and fractionation into cytosol and membrane fractions as
described above (subcellular fractionation) or lysis in lysis
buffer (PBS, 1% NP40, aprotinin (Sigma, St.Louis, MO)
and 0.5% phosphatase inhibitor cocktail II (Sigma) on ice
for 30 minutes. Protein concentrations were estimated by
Ponceau red (Sigma) staining of dot blots on nitrocellu-
lose membranes (Schleicher and Schuell GmbH, Dassel,
Germany) by comparison with proteins of known con-
centration. 1 ug polyclonal antibody was used to
precipitate the EphA2 receptor over night at 4°C, and the
antibody-complex was captured with protein-G sepharose
(Pharmacia). After three times washing with TBS + 0.1%
Tween20, captured proteins were eluted by boiling in 3 ×
SDS sample buffer. PAGE was performed with indicated
lysates or immunoprecipitates. The Western blot was
immunoblotted with indicated antibodies and visualized
(ECL+, Amersham). The filter was stripped and reprobed
with polyclonal α-EphA2.
Cell staining and flow cytometry analysis
Cell surface staining
Cells were pre-incubated with 0.1 mg/ml human aggre-
gated gamma globulin to block unspecific staining, then
incubated with 20 ug/ml fusion protein or antibody for
30 min. at 4°C. The cells were washed twice, and stainedBMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/9
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with the indicated anti-mouse conjugated secondary anti-
body. 10000 cells were analyzed.
Intracellular staining
CD4+ T cells co-incubated with LLDC in the presence of
immobilized fusion protein were re-stimulated with 2,5
ug/ml TPA and 250 ng/ml ionomycin for 5 hour, and 10
ug/ml brefeldinA (Sigma) was added the last 2–3 hours.
Intracellular staining was performed using the Fix and
Perm cell permeabilization kit (Caltag laboratories), as
described by the manufacturer. 104 cells were analyzed by
a FACSCalibur flow cytometer, and the analyses were per-
formed with CELLQuest software (Becton Dickinson).
10000 cells were analyzed.
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